“By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well positioned to drive long-term shareholder value. Together, we believe we can deliver significant benefits to patients with mRNA-based immunotherapies and realize our full potential in a combined company,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac (CVAC). “The proposed transaction will bring together some of Europe’s best mRNA scientists and can create significant opportunities across our collective research, development and manufacturing platforms, while establishing the combined company as a global leader in mRNA-based medicines.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- GSK provides update on U.S. settlement CureVac/BioNTech mRNA patent litigation
- CureVac Resolves Patent Litigation with Pfizer/BioNTech
- CureVac Announces Key Resolutions from Annual Shareholders Meeting
- CureVac downgraded to Neutral from Buy at UBS
- CureVac Announces Key Appointments and Auditor Reappointment at Annual Meeting